Dingdang Health Technology Group Ltd. disclosed a Next Day Disclosure Return showing continued execution of its share repurchase programme.

The company repurchased 621,000 ordinary shares on 5 June 2026 via on-market transactions at prices ranging from HKD 0.79 to HKD 0.87, for an aggregate consideration of HKD 0.53 million.

Including this latest tranche, Dingdang Health has bought back 7.39 million shares between 19 May and 5 June 2026 that are earmarked for cancellation but had not yet been cancelled as of 5 June. The cumulative purchases represent approximately 0.59 % of the company’s 1.25 billion issued shares and were executed at an estimated average price of HKD 0.90, bringing total cash outlay during the period to about HKD 6.64 million.

Despite the buybacks, the company’s issued share capital remained unchanged at 1,254.65 million shares as of 5 June 2026, pending the formal cancellation of the repurchased stock.

Under the repurchase mandate granted on 28 May 2025, Dingdang Health is authorised to repurchase up to 131.95 million shares. To date, 72.22 million shares, or 5.47 % of the issued share base on the mandate date, have been repurchased on the market. In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issues until 5 July 2026.